Drugs / Tegoprubart
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06972069 | May 2025 → Dec 2030 expected | disease related to solid organ transplantation, kidney failure | Tatsuo Kawai, MD, PhD | Active not recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07592000 | Apr 2027 → Jan 2030 expected | chronic kidney disease, type 1 diabetes mellitus | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06305286 | Mar 2024 → Mar 2029 expected | type 1 diabetes mellitus | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05480657 | Sep 2022 → Aug 2024 | type 1 diabetes mellitus | Eledon Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05027906 | Feb 2022 → Jan 2027 expected | — | Eledon Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06126380 | Oct 2023 → Dec 2029 expected | transplant rejection | Eledon Pharmaceuticals | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05983770 | Aug 2023 → Sep 2025 | transplant rejection | Eledon Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT05125068 | Mar 2022 → Jul 2023 | IgA glomerulonephritis | Eledon Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04711226 | Feb 2021 → Jun 2024 | type 1 diabetes mellitus | Anelixis Therapeutics, LLC | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04322149 | Oct 2020 → Mar 2022 | amyotrophic lateral sclerosis | Anelixis Therapeutics, LLC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07835581 | Oct 2026 → Mar 2029 expected | transplant rejection | Eledon Pharmaceuticals | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-09-22 | Eledon Pharmaceuticals | Results Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society eledon.com ↗
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24 |
| 2026-09-03 | Eledon Pharmaceuticals | Regulatory Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 eledon.com ↗
IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes |
| 2026-06-22 | Eledon Pharmaceuticals | Results Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus eledon.com ↗
Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61 mL/min/1.73 m²; p<0.05) |
| 2026-06-08 | Eledon Pharmaceuticals | Results Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine eledon.com ↗ |
| 2026-03-16 | Eledon Pharmaceuticals | Results Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine eledon.com ↗
The data demonstrated rapid improvement in glycemic control following islet transplantation, with stable islet graft function observed across the cohort. |
| 2026-03-10 | Eledon Pharmaceuticals | Regulatory Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation eledon.com ↗
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation. |
| 2026-01-23 | Eledon Pharmaceuticals | Results Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium eledon.com ↗
Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months. |
All press releases naming this drug 10 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegoprubart | “This study aimed to assess the safety, tolerability, and impact on pro-inflammatory biomarker profiles of an anti CD40L antibody, tegoprubart, in individuals with amyotrophic...” PMID 39480764 ↗ Oct 2024 |
| Known as | AT-1501 | “Tegoprubart (AT-1501) is a monoclonal antibody for Injection is a humanized immunoglobulin G1 (IgG1) kappa monoclonal anti-CD40L antibody that blocks CD40L binding to its...” NCT06305286 ↗7“AT-1501 monoclonal antibody targeting CD40L given as an IV infusion” NCT04322149 ↗ |
| Action | Inhibit | “a humanized monoclonal antibody antagonist to CD40 ligand (CD40L)” NCT04322149 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody antagonist to CD40 ligand (CD40L)” NCT04322149 ↗ |
| Route | Intravenous | “AT-1501 monoclonal antibody targeting CD40L given as an IV infusion” NCT04322149 ↗ |
| Target | CD40LG | “AT-1501 monoclonal antibody targeting CD40L given as an IV infusion” NCT05027906 ↗ |